Research programme: small molecule therapeutics - Anagenex
Latest Information Update: 23 Jun 2022
At a glance
- Originator Anagenex
- Class Antineoplastics; Cardiovascular therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Cardiovascular disorders